<DOC>
	<DOCNO>NCT01875224</DOCNO>
	<brief_summary>This study conduct determine belatacept appropriate alternative immunosuppressive medication ( reduce immune system 's effect ) kidney transplant patient develop new onset diabetes transplant ( NODAT ) . Patients diagnose NODAT approach opportunity participate study . If agree participate , randomize one-to-one ( like coin flip ) study arm ( belatacept ) control arm ( current medication regimen ) . If patient randomize study arm , taper current regimen start receive monthly belatacept infusion . The control arm mean patient continue current , standard care medication , follow tacrolimus trough level indicate within study protocol . Different laboratory test ( i.e . fast blood glucose ) measure study monitor progression NODAT patient .</brief_summary>
	<brief_title>Comparison NODAT Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Written informed consent must give patient . Adult patient age 18 65 Thymoglobulin induction time transplant Patient must EpsteinBarr Virus seropositive Patient receive blood type incompatible transplant , Tcell Bcell positive crossmatch Patients Hepatitis B , Hepatitis C , HIV clinically significant systemic infection within 30 day prior transplant History stroke , severe cardiac disease cardiac failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>kidney transplant</keyword>
	<keyword>diabetes transplant</keyword>
	<keyword>belatacept</keyword>
</DOC>